[Form 3] SOPHiA GENETICS SA Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

SOPHiA GENETICS SA director Kathy L. Hibbs filed an initial ownership report showing holdings in ordinary shares and share options. She reports 97,276 ordinary shares, including 33,784 shares underlying restricted share units that vest in full at the company’s next annual shareholder meeting, subject to continued service. She also holds fully vested and exercisable options over 140,000 ordinary shares at an exercise price of 5.9800 per share expiring on March 26, 2031, and options over 49,751 ordinary shares at 3.0400 per share expiring on June 18, 2035.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

HIBBS KATHY L

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK, 5TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	97,276(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	03/26/2031	Ordinary Shares	140,000	$5.98	D
Share Option (Right to Buy)	(3)	06/18/2035	Ordinary Shares	49,751	$3.04	D

Explanation of Responses:

1. Includes 33,784 ordinary shares to be delivered in settlement of a restricted share unit award ("RSU"). Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2025 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.

2. The share options are fully vested and exercisable.

3. The share options were granted on June 18, 2025 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney

	/s/ Elimara Brunetto as Attorney-in-Fact for Kathy L. Hibbs	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Kathy L. Hibbs report in her Form 3 for SOPH?

Kathy L. Hibbs reports her initial ownership in SOPHiA GENETICS SA, including ordinary shares, restricted share units, and share options. The filing details current holdings and vesting terms, but shows no new purchases or sales of SOPH securities.

How many SOPHiA GENETICS (SOPH) ordinary shares does Kathy Hibbs hold?

Kathy Hibbs reports beneficial ownership of 97,276 ordinary shares of SOPHiA GENETICS SA. This total includes 33,784 shares that will be delivered upon settlement of restricted share units, subject to vesting at the next annual shareholder meeting and her continued service.

What restricted share units (RSUs) are disclosed in the SOPH Form 3?

The Form 3 states that 33,784 ordinary shares will be delivered upon settlement of a restricted share unit award. Each RSU equals one SOPHiA GENETICS ordinary share and vests 100% at the issuer’s next scheduled annual shareholder meeting, contingent on Kathy Hibbs’s continued service.

What share options does Kathy Hibbs hold in SOPHiA GENETICS (SOPH)?

Kathy Hibbs holds fully vested options over 140,000 ordinary shares at an exercise price of 5.9800 per share, expiring March 26, 2031. She also holds options over 49,751 shares at 3.0400 per share, expiring June 18, 2035, both reported as directly owned.

Are Kathy Hibbs’s SOPH share options vested and exercisable?

One option grant for 140,000 SOPHiA GENETICS ordinary shares is described as fully vested and exercisable. Another grant for 49,751 shares was granted June 18, 2025 and is scheduled to vest 100% at the issuer’s next annual meeting, subject to her continued service.

Does the SOPH Form 3 show any insider buying or selling activity?

The Form 3 functions as an initial ownership report and lists holdings in ordinary shares, RSUs, and options. The transaction summary indicates three holding entries with unknown transaction codes and no buy or sell transactions reported for SOPHiA GENETICS securities.